PA5-78512

antibody from Invitrogen Antibodies

Targeting: PARP14 ARTD8, KIAA1268, pART8

Western blot (Data presented on provider website)

Immunoprecipitation (Recommended by provider)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-78512

Provider

Invitrogen Antibodies

Product name

PARP14 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Positive Control: U87-MG, SK-N-SH, SK-N-AS Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1.29 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors.

Ujvari D, Malyukova A, Zovko A, Yektaei-Karin E, Madapura HS, Keszei M, Nagy N, Lotfi K, Björn N, Wallvik J, Stenke L, Salamon D
Oncoimmunology 2022;11(1):2109861

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 7. IFNgamma upregulates the expression of several key anti-apoptotic genes in imatinib-treated primary human CD34+ CML stem/progenitor cells. (a) Relative mRNA levels of selected key anti-apoptotic genes normalized to EEF1A1, quantified by real-time RT-PCR in primary human CD34+ CML stem/progenitor cells (obtained from the peripheral blood of Patient No. 4) left untreated or treated for 18 hours with 5 muM imatinib (IM) and/or 5 ng/ml IFNgamma. (b) Relative mRNA levels of selected key anti-apoptotic genes normalized to EEF1A1, quantified by real-time RT-PCR in primary human CD34+ CML stem/progenitor cells (obtained from the peripheral blood of Patient No. 5) left untreated or treated for 90 minutes with 5 muM imatinib (IM) and/or 5 ng/ml IFNgamma in the absence (w/o cytokines) or presence of SCF, FL, and TPO. (c) Relative mRNA levels of selected key anti-apoptotic genes normalized to EEF1A1, quantified by real-time RT-PCR in primary human CD34+ CML stem/progenitor cells (obtained from the peripheral blood of Patient No. 6) left untreated or treated for 90 minutes with 5 muM imatinib (IM) and/or 5 ng/ml IFNgamma in the absence of cytokines. (d) Immunoblot analysis of BCL-XL, MCL-1L, PARP9, PARP14 and beta-actin protein expression in total cell extracts of CD34+ stem/progenitor cells (obtained from the peripheral blood of Patients Nos. 2, 3 and 7) left untreated (-) or treated (+) for 18 hours with 5 muM imatinib and/or 5 ng/ml IFNgamma. PIM1 and PIM2 proteins were expre